Influence of age and comorbidities on the chemotherapeutic management of lung cancer
- 1 October 2001
- journal article
- review article
- Published by Elsevier in Lung Cancer
- Vol. 33, S115-S120
- https://doi.org/10.1016/s0169-5002(01)00311-7
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Comorbidity and functional status are independent in older cancer patients.Journal of Clinical Oncology, 1998
- Oral etoposide and palliative treatment for small-cell lung cancerThe Lancet, 1996
- Attenuated‐dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical resultsBritish Journal of Haematology, 1995
- Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal functionCancer Treatment Reviews, 1995
- Neurotoxicity of antineoplastic agentsCritical Reviews in Oncology/Hematology, 1993
- Geriatric Pharmacology: Basic and Clinical Considerations*Annual Review of Pharmacology and Toxicology, 1992
- Retrospective review of chemotherapy for small cell lung cancer in the elderly: Does the end justify the means?European Journal of Cancer and Clinical Oncology, 1991
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976
- “Mini-mental state”Journal of Psychiatric Research, 1975